Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (24131)	8/7/1998 9:56:00 AM
From: Henry Niman	Respond to of 32384

Actually, LGND targets many diseases, but I suspect that some posters on this thread are really beyond help.

To: Hippieslayer who wrote (24131)	8/7/1998 10:07:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Even their latest patent won't help: United States Patent 5,786,178 Niman, et. al. Jul. 28, 1998 Polypeptide-induced monoclonal receptors to protein ligands Inventors: Niman; Henry L. (Carlsbad, CA); Lerner; Richard A. (LaJolla, CA). Assignee: The Scripps Research Institute (La Jolla, CA). Appl. No.: 300,068 Filed: Sept. 2, 1994 Related U.S. Application Data Continuation of (including streamline cont.) Ser. No. 772,702, Oct. 7, 1991, abandoned, which is a continuation of Ser. No. 736,545, May 21, 1985, abandoned, which is a continuation-in-part of Ser. No. 701,954, Feb. 15, 1985, Pat. No. 5,030,565. Intl. Cl. : C12P 21/04 Current U.S. Cl.: 435/69.6; 435/172.3; 435/240.27; 435/70.2; 435/70.21; 436/518; 530/387.7; 530/388.8; 530/389.7; 935/15 Field of Search: 435/69.6, 240.27, 320.1, 172.3, 70.2, 70.21; 530/387, 389, 388.1, 388.2, 388.8; 935/12, 15; 436/518 References Cited \| [Referenced By] Other References Lerner, Nature 299: 592-596 (1986) Tapping the Immunological Repetoire to Produce Antibodies. Niman et al, PNAS 80:4949-4953 (1983) Generation of Protein-Reactive Antibodies by Short. Primary Examiner: Scheiner; Laurie Assistant Examiner: Stucker; Jeffrey Attorney, Agent or Firm: Lyon & Lyon LLP Abstract Monoclonal receptors raised to immunogenic polypeptides whose amino acid residue sequences correspond to sequences of oncoprotein ligands are disclosed, as are method for the production of those receptors and products and methods that utilize them. The monoclonal receptors bind both to the oncoprotein ligand to a portion of which the polypeptide corresponds in sequence, and to the immunogenic polypeptide to which the receptors were raised. 11 Claims, 34 Drawing Figures This invention was made with government support under Public Health Service Contract NO1-CP-41009, Public Health Service Grants CA 38160 and CA 25803 awarded by the National Institutes of Health. The government has certain rights in the invention.